Teladoc Health AI Price Prediction

The negative EPS and PE ratio indicate Teladoc Health remains unprofitable, with the market assigning no earnings-based valuation support. Persistent losses suggest structural profitability challenges rather than a short-term dip. Without clear evidence of an imminent shift to positive earnings, the financial profile is a headwind for the stock.

• Negative EPS of -1.26 and a PE ratio of -4.56 confirm the business is loss-making, limiting traditional valuation support.
• A negative PE typically reflects either a turnaround story or ongoing structural issues; paired with a sharply falling stock price, the market appears more concerned about the latter.
• Until there is a visible path to sustained positive net income and improving margins, the financial performance remains a drag on investor sentiment.

Teladoc Health’s share price at $5.74, down 18% in the last month, is trading well below its 200-day moving average of $7.57, signaling a pronounced downtrend. The RSI at 34.31 is near oversold territory, showing selling pressure has been strong but not yet at an extreme reversal signal. Overall, the technical setup points to a weak trend with only a tentative case for a short-term bounce.

• Price ($5.74) is significantly below the 200-day moving average ($7.57), a classic sign of a sustained bearish trend and negative long-term momentum.
• An 18% decline over the last month reflects strong recent selling pressure and likely negative sentiment or disappointment around fundamentals or outlook.
• RSI at 34.31 is close to the oversold threshold (30), suggesting downside momentum has been heavy, but there is not yet a clear technical reversal signal; risk of further weakness remains.

Teladoc Health’s stock currently reflects a bearish setup, driven by ongoing losses, a negative earnings profile, and a clear downward price trend below its long-term moving average. While digital engagement and social metrics are relatively stable, they are not strong enough to counterbalance weak profitability and negative technical momentum. Absent a clear catalyst for earnings improvement or a decisive technical reversal, the risk-reward profile skews cautious.

• Persistent unprofitability and a negative PE, combined with a sharp recent price drop and trading well below the 200-day moving average, tilt the outlook bearish.
• Alternative data shows stability rather than strong growth, suggesting the business is not currently experiencing a major demand acceleration that could quickly transform the earnings picture.